Page 36 - Read Online

Page 10 of 11 Heft Neal et al. J Cancer Metastasis Treat 2019;5:76 I http://dx.doi.org/10.20517/2394-4722.2019.32

28. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009;229:12-26.
29. Ariffin AB, Forde PF, Jahangeer S, Soden DM, Hinchion J. Releasing pressure in tumors: what do we know so far and where do we go from
here? A review. Cancer Res 2014;74:2655-62.
30. Farsaci B, Donahue RN, Coplin MA, Grenga I, Lepone LM, et al. Immune consequences of decreasing tumor vasculature with
antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol Res 2014;2:1090-102.
31. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, et al. Vascular normalization in Rgs5-deficient tumours promotes immune
destruction. Nature 2008;453:410-4.
32. Allen CT, Clavijo PE, Van Waes C, Chen Z. Anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape
and immunotherapeutic approaches. Cancers 2015;7:2397-414.
33. Economopoulou P, Perisanidis C, Giotakis EI, Psyrri A. The emerging role of immunotherapy in head and neck squamous cell carcinoma
(HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med 2016;4:173.
34. Fujii N, Shomori K, Shiomi T, Nakabayashi M, Takeda C, et al. Cancer-associated fibroblasts and CD163-positive macrophages in oral
squamous cell carcinoma: their clinicopathological and prognostic significance. J Oral Pathol Med 2012;41:444-51.
35. Spanos WC, Hoover A, Harris GF, Wu S, Strand GL, et al. The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13
loss, which allows anchorage-independent growth and synergizes with ras for invasive growth. J Virol 2008;82:2493-500.
36. Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in
patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol
2019;20:1083-97.
37. Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, et al. Tadalafil augments tumor specific immunity in patients with head and neck
squamous cell carcinoma. Clin Cancer Res 2015;21:30-8.
38. Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from
cancer patients. J Clin Invest 2013;123:1580-9.
39. Hoesli R, Birkeland AC, Rosko AJ, Issa M, Chow KL, et al. Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in
persistent/recurrent laryngeal squamous cell carcinoma. Oral Oncol 2018;77:83-9.
40. Mandal R, Senbabaoglu Y, Desrichard A, Havel JJ, Dalin MG, et al. The head and neck cancer immune landscape and its immunotherapeutic
implications. JCI Insight 2016;1:e89829.
41. Ono T, Azuma K, Kawahara A, Sasada T, Hattori S, et al. Association between PD-L1 expression combined with tumor-infiltrating
lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma. Oncotarget 2017;8:92699-714.
42. Young MR, Wright MA, Lozano Y, Prechel MM, Benefield J, et al. Increased recurrence and metastasis in patients whose primary head and
neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells.
Int J Cancer 1997;74:69-74.
43. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336-47.
44. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, et al. Type I interferon is selectively required by dendritic cells for
immune rejection of tumors. J Exp Med 2011;208:1989-2003.
45. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses
through CD8 {alpha}+ dendritic cells. J Exp Med 2011;208:2005-16.
46. Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014;50:627-32.
47. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and
combinations. Sci Transl Med 2016;8:328.
48. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015;125:3384-91.
49. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic
biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73:128-38.
50. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of
HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013;73:1733-41.
51. Ukpo OC, Thorstad WL, Lewis JS Jr. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal
squamous cell carcinoma. Head Neck Pathol 2013;7:113-21.
52. Tran L, Allen CT, Xiao R, Moore E, Davis R, et al. Cisplatin alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition in head
and neck squamous cell carcinoma. Cancer Immunol Res 2017;5:1141-51.
53. de Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical
evidence. Clin Cancer Res 2014;20:5384-91.
54. Hato SV, Khong A, de Vries IJ, Lesterhuis WJ. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin
Cancer Res 2014;20:2831-7.
55. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, et al. Radiation modulates the peptide repertoire, enhances MHC class I
expression, and induces successful antitumor immunotherapy. J Exp Med 2006;203:1259-71.
56. Klein B, Loven D, Lurie H, Rakowsky E, Nyska A, et al. The effect of irradiation on expression of HLA class I antigens in human brain
tumors in culture. J Neurosurg 1994;80:1074-7.
57. Santin AD, Hiserodt JC, Fruehauf J, DiSaia PJ, Pecorelli S, et al. Effects of irradiation on the expression of surface antigens in human
ovarian cancer. Gynecol Oncol 1996;60:468-74.
58. Santin AD, Rose GS, Hiserodt JC, Fruehauf J, Eck LM, et al. Effects of cytokines combined with high-dose gamma irradiation on the
expression of major histocompatibility complex molecules and intercellular adhesion molecule-1 in human ovarian cancers. Int J Cancer
1996;65:688-94.
59. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, et al. Local radiation therapy of B16 melanoma tumors increases the generation
of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005;174:7516-23.